National Survey on Dyslipidemic Patients (PRYSME)
Survey on Time to Lipid-lowering Drug Implementation on Dyslipidemic Patients in General Practice.
Sponsor: AstraZeneca
Listed as NCT00701402, this observational or N/A phase trial focuses on Dyslipidemia and remains completed. Sponsored by AstraZeneca, it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jun 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Abbaretz, France , Abbeville, France , Ablon-sur-Seine, France , Abrest, France , Agde, France , Agen, France , Ahuy, France , Aignay-le-Duc, France , Aigre, France , Aigues-Mortes, France and 1186 more locations